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http:WHAT THIS PAPER ADDS
This review demonstrates that quality of evidence behind the use of deep venous stenting to treat obstructive
chronic venous disease is weak. However, the consistent effects and marked changes to disease course mean
that it should be considered as an acceptable treatment. This review intended to inﬂuence clinical practice so
vascular teams are aware of this, and it will serve to guide the future research that is needed.Objectives: Deep endovenous stenting to relieve chronic venous disease (CVD) secondary to post-thrombotic or
non-thrombotic iliac vein obstruction is becoming increasingly well described. However, current and adequately
reported systematic reviews on the topic are lacking. This report aimed to produce a systematic review and meta-
analysis of the available data, reported to the Preferred Reporting Items for Systematic reviews and Meta-
Analyses guideline.
Methods: MEDLINE, EMBASE, and the Cochrane Central Register for Controlled Trials databases and key
references were searched.
Results: Sixteen studies were included (14 before-and-after studies, 1 controlled before-and-after study, and 1
case series) encompassing successful deep venous stenting in 2,373 and 2,586 post-thrombotic or non-
thrombotic limbs and patients respectively. The data were too heterogeneous to perform a meta-analysis. There
were signiﬁcant improvements in validated measures of the severity of CVD and venous disease-speciﬁc quality
of life. Persistent ulcer healing rates ranged from 56% to 100% in limbs that had often already failed conservative
management. Primary and secondary stent patency ranged from 32% to 98.7% and 66%e96% respectively. The
major complication rate ranged from 0 to 8.7% per stented limb. A GRADE assessment demonstrated the quality
of the evidence for ﬁve outcomes to be “Very Low” and one to be “Low” (ulcer healing).
Conclusions: The quality of evidence to support the use of deep venous stenting to treat obstructive CVD is
currently weak. The treatment does however appear promising and is safe and should therefore be considered as
a treatment option while the evidence base is improved.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Chronic venous disease (CVD) is common and is deﬁned as a
“morphological or functional abnormality of the venous
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//dx.doi.org/10.1016/j.ejvs.2015.09.002from mild leg pain to skin changes, venous claudication, or
ulceration. CVD can result from primary or secondary cau-
ses, for example where CVD occurs after deep vein
thrombosis (DVT), it is known as the post-thrombotic syn-
drome (PTS),1 and from extrinsic iliac vein compression, it is
known as non-thrombotic iliac vein lesions (NIVLs).
PTS is the most frequent chronic complication of DVT,
affecting up to half of patients despite adequate anti-
coagulation,2,3 and carries signiﬁcant negative impacts on
quality of life (QOL)4 and on the economy.5 The patho-
physiology of PTS is thought to be due to venous hyper-
tension from residual obstruction and deep venous reﬂux
Endovenous stenting in chronic venous disease 101secondary to valve damage.6 Only 20e30% of iliac vein
DVTs fully recananalise7,8 and residual obstruction following
iliofemoral DVT is associated with severe CVD.9 Surgical
bypass of occluded veins has now been largely superseded
by endovenous stenting to treat severe obstructive venous
disease.10,11
When symptomatic, the pulsatile compression of the left
common iliac vein by the right common iliac artery on the
ﬁfth lumbar vertebra is referred to as the MayeThurner
syndrome.12 Several other anatomical variants have been
described in the literature, such that these lesions are now
collectively referred to as (NIVLs). NIVL may present as a
DVT or with CVD. For those presenting with CVD, endo-
vascular stenting is rapidly becoming the treatment of
choice over traditional surgical repair.13
Despite the widespread recommendation10,11 of endo-
vascular stenting for CVD related to outﬂow obstruction
from post-thrombotic changes or NIVL, the one systematic
review dedicated to the topic14 was not reported to rec-
ognised standards15 and was conducted over 2 years ago.
This report aims to present an updated systematic review
and meta-analysis of the available data regarding the efﬁ-
cacy and safety of venous stenting in CVD due to post-
thrombotic or NIVL obstruction.
MATERIALS AND METHODS
The Preferred Reporting Items for Systematic Reviews and
Meta-analyses guidelines15 were followed. The aims of the
study, eligibility criteria, and outcomes were predeﬁned in a
protocol.
Ethics approval was not required.Eligibility criteria
All observational and randomised studies, as deﬁned using
the Cochrane Handbook ‘List of study design features’,16
were eligible except cross-sectional studies. Participants of
all ages suffering from CVD related to post-thrombotic or
NIVL obstruction, conﬁrmed on imaging, were included if
they received endovenous iliac vein stenting with or
without extension of the stent stack (group of adjacent
overlapping stents) into the inferior vena cava (IVC) or
common femoral vein (CFV) and more caudally or with or
without the use of concurrent superﬁcial venous pro-
cedures. A minimum of 20 eligible stented limbs and 6
months’ follow-up was required. Studies were excluded if
they did not report on any of the deﬁned outcomes, if
stenting was performed within 6 months of DVT in the
stented segment, or if the study populations had CVD
related only to obstruction from other causes, for example
malignancy. No restriction was made on publication type,
language, or date. The primary outcome was any change in
severity of CVD as determined by validated measures or
scores such as the clinical component of the clinical, aeti-
ology, anatomy, and pathophysiology classiﬁcation (C of
CEAP),17 the Venous Clinical Severity Score (VCSS),18 or
validated measures of PTS severity such as the Villalta
score.19 Secondary outcomes were validated CVD-speciﬁcQOL scores such as the Chronic Venous Insufﬁciency
Questionnaire (CIVIQ)20 and revisions thereof, the Venous
Disability Score (VDS),18 the Venous Insufﬁciency Epidemi-
ological and Economic Study instrument (VEINES-QOL/
Sym),21 or generic QOL scores such as the 36-Item Short
Form Health Survey (SF-36);22 rates of ulcer healing; reports
on other signs or symptoms of CVD such a pain or oedema;
primary, assisted-primary (AP) and secondary stent patency
and complications. A complication was considered major if
an event led to surgery or medical management with likely
signiﬁcantly prolonged hospitalisation or it led to further
endovascular intervention. Owing to suspected heteroge-
neity in what complications were reported, the complica-
tions have been presented as described in the reports,
expressed as a percentage rate per limb stented.Information sources and search strategy
On July 2, 2015, the Ovid portal (1946 to present) was used
to search the MEDLINE and EMBASE databases. The
Cochrane Central Register of Controlled Trials was searched
simultaneously. The references of included studies and
other important publications were hand searched for
additional reports.Study selection
All articles located in the initial search strategy had their
abstracts and titles independently screened by two authors
(M.S. and A.B.) with any discrepancies resolved by discus-
sion. M.S. and A.B. subsequently reviewed the selected full
citations to see if they met the eligibility criteria and hand-
searched references for further studies. If only an abstract
had been published, the authors were contacted for full
methodology and results. If this could not be provided, the
study was excluded. To avoid the inclusion of duplicate
publications of the same data, the data were examined for
similarities (e.g. identical start and end dates), and if
necessary the authors contacted for clariﬁcation.Data collection process and data items
Two authors (M.S. and A.B) extracted the data from the
included studies in a predesigned proforma. Data were
extracted for study design;16 start and end dates; de-
mographics; inclusion criteria; the aetiology of venous
obstruction (post-thrombotic or NIVL); the number of pa-
tients and limbs where stents were attempted and suc-
cessfully deployed; whether the lesion was stenotic or a
chronic total occlusion (CTO) (i.e. requiring recanalisation);
the presence of concurrent superﬁcial or deep venous
reﬂux; stent type, and stent site (above vs. below the
inguinal ligament and extending stents into the IVC); the
time of stenting after DVT (where applicable); the concur-
rent use of balloon angioplasty; the concurrent use of su-
perﬁcial venous procedures or other venous surgeries; the
outcomes; the antithrombotic regimens used; and the
number of withdrawals/loss to follow-up per study. For
studies where not all of these data were available, the
102 M.J. Seager et al.authors were contacted and any unpublished data obtained
is highlighted.
Risk of bias
It became clear from initial literature searches that rando-
mised controlled trials (RCTs) in the ﬁeld were lacking. The
included studies were assessed for several key biases by
M.S. and A.B.:16 selection bias, performance bias, detection
bias, attrition bias, and selective reporting bias. Attrition
bias was deemed a high risk if the follow-up rate was less
than 80%, in the absence of systematic examination of
those participants who were lost to follow-up. Bias was also
evaluated at outcome level using the GRADE assessment of
the evidence.23
Summary measures and synthesis of results
Owing to the lack of control groups and the heterogeneous
inclusion criteria and outcomes in the studies, it was not
deemed appropriate to perform a meta-analysis of the data
and planned formal sub-group analyses were not possible
(post-thrombotic versus NIVL; CTO versus stenosis; stent
site (extension below the inguinal and into the IVC); stent
type; the use of concurrent superﬁcial venous procedures
and the presence/absence of deep or superﬁcial reﬂux). Any
data looking at the effect of these variables within the
included studies were extracted and reported.
RESULTS
Study selection
The search strategy yielded 2,058 results, with 1,821 articles
for title and abstract screening once duplicates were
removed. Of these, 140 articles were selected for consid-
eration of full text and 16 of these articles met the deﬁned
eligibility criteria.24e39 One group published further data
with more patients in a second publication,27 but the
original publication28 is also referenced as it contains data
not reported in the second publication. The more recent,
larger dataset is referenced except when the older dataset
is speciﬁcally referred to. Fifteen unique studies were
therefore identiﬁed in the literature search and hand
searching of key references identiﬁed an additional one40
(Fig. 1).
Study characteristics
Fourteen studies were before-and-after studies,24e27,29,31e
36,38e40 one was a controlled before-and-after study30 and
one was a case series.37 Endovascular stenting was
attempted in 2,649 limbs of 2,431 patients with procedural
success in 2,586 (97.6%) and 2,373 (97.6%) respectively.
Outcome data from control non-stented limbs were avail-
able for nine limbs in one study.30 Age ranged between a
median of 3932 and 58 years24,37 and the female/male ratio
ranged between 0.630 and 4.2.31 Two out of 16 studies
considered only patients with NIVL (a total of 507 and 483
procedures attempted in limbs and patients respec-
tively),25,34 seven considered only patients with PTS (509limbs and 474 patients)24,26,30,36,38e40 and seven evaluated
a mixture,27,29,31e33,35,37 with two studies also reporting on
a small number of patients who received stents for CVD due
to other aetiologies.31,32 In four studies, all patients had
CTO before stenting (a total of 385 limbs),32,36,39,40 in nine
studies there was a mixture of CTO or stenotic lesions
(proportions variably speciﬁed as displayed in
Table 1)24,26,29e31,34,35,37,38 and in three studies the case
mix could not be established despite attempting to contact
authors.25,27,33 All studies performed angioplasty before
stenting, apart from one where it was not stated.36 The
remainder of the extracted data is summarised in Table 1.
Quality assessment of studies
The overall quality of the included studies was weak. No
RCTs, cohort studies or caseecontrol studies that met the
inclusion criteria were identiﬁed. One study had a control
group30 and these nine contralateral non-stented limbs
were not comparable to the intervention group, as the
median C component of CEAP was different at baseline.
Three of the more recent reports were conducted pro-
spectively,24,27,33 otherwise they were retrospec-
tive25,26,29,30,32,34e40 and in one case it was not clear.31
Fig. 2 summarises the bias assessment (see also the table
in the Supplementary material).
A general strength of the included studies was that
several consisted of a substantial number of stented limbs
(over 150).25,27,34e37
Outcomes and grading of the evidence
Using the GRADE approach,23 for ﬁve of the six deﬁned
outcomes, the quality of evidence was rated as “very low”
and for ulcer healing it was rated as “low” (Table 2).
Severity of CVD
Five studies reported one or more of the deﬁned measures
of CVD severity with sufﬁcient follow-up duration (a total of
295 stented patients).24,26,30,31,39 Delis et al.30 demon-
strated a signiﬁcant improvement (p < .01) in median CEAP
class from C3 (C3e6) to C2 (C2e6) after stenting in 23 PTS
limbs at a median of 8.3 months follow-up (100% follow-up
rate). There was no change from the baseline C2 (C0e4)
CEAP class in the nine contralateral non-stented control
limbs. Hartung and colleagues31 found median VDS
decreased from 2 to 1 (0e3) at a median of 38 months’
follow-up (100% follow-up rate), but the statistical signiﬁ-
cance is unclear. Blanch Alerany and colleagues26 found
signiﬁcant improvements in mean Villalta and VCSS scores
(p < .0001) following stenting from 15 (10e28) to 2 (0e11)
and 8 (5e17) to 2 (0e9) respectively at a mean of 21
months in their study of 36 PTS patients (29/39 limbs and
12/39 at 12 and 24 month follow-up respectively). Patients
whose stents occluded during follow-up, and refused sec-
ondary interventions, experienced a sustained, but smaller,
decrease in VCSS of at least four points.26 Sarici et al.24
showed signiﬁcant reductions (p < .0001) in median Vil-
lalta and VCSS scores of 18 (interquartile range (IQR) 7e30)
Figure 1. PRISMA ﬂow diagram summarising the results of the application of the search strategy at each stage.
Endovenous stenting in chronic venous disease 103to 8 (4e19) and 14 (6e28) to 5 (3e17) respectively in 52
PTS patients at 6 months’ follow-up (100% follow-up rate),
with less marked improvements in the ﬁve patients whose
stents occluded. Ye et al.39 showed the mean Villalta score
fell from 22.0  4.3 to 9.3  2.6 in 87 of their PTS patients
at a median 25-month follow-up.
Other signs and symptoms of CVD
All but two studies27,37 reported other signs and symptoms
of CVD, predominantly oedema and pain, totalling 1,984
patients who received stents (Table 3).
Ulcer healing
Twelve of the included studies described data on ulcer
healing (a total of 400 ulcers).24e26,30,31,33e36,38e40 The rate
of persistent ulcer healing ranged from 56% in a large studyof 167 CTO PTS limbs36 to 100% in several smaller
studies.26,31,38 The study with the largest number of pa-
tients with ulcers at baseline described a cumulative 5-year
healing rate of 58% of the 148 baseline ulcers.35 Six studies
speciﬁcally stated that the participants had failed conser-
vative management,26,30,31,34,38 and in one study the ulcers
had failed to heal after endovenous laser varicosity abla-
tion.25 In a further two studies the authors were contacted
to conﬁrm the patients had indeed failed conservative
management.35,36 The ulcer healing data are summarised in
Table 3.Quality of life measures
Three studies reported changes in CVD-speciﬁc QOL scores
following stenting24,28,36 and one also included a general
QOL score (SF-36).28 Raju and Neglen36 found signiﬁcant
Table 1. Summary of the included studies.
Study Study design Inclusion criteria Age Female/
male
ratio
Exclusion criteria Sample size
patients (No.
limbs):
aetiology PTS,
NIVL
Stent type
(in no. limbs
unless
otherwise
stated)
Stenosis/CTO
(no. limbs
unless
otherwise
stated)
Concurrent
reﬂux at
baseline/
limb (unless
otherwise
stated)
Concurrent
endovascular/
surgical deep or
superﬁcial venous
interventions
Antithrombotic
regimen
Relevant
outcomes
reported at
6 months
Delis
200730
Retrospective
controlled
before and
after study
CVD due to chronic iliofemoral
DVT on venogram þ failure 1
year conservative management
(elastic compression  ulcer
care)
Median
42 (IQR
40e56,
range
31e77)
0.6 Failure of
endovascular
therapy; peripheral
arterial disease
(resting ABPI < 1);
unable to undergo
plethysmography
16 (23): 23 PTS;
9 contralateral
unstented limbs
as control cases
Wallstent,
S.M.A.R.T.,
Gianturco
(proportions
not stated)
Combination
(not
speciﬁed)
5/23
superﬁcial
alone
intervention
arm and 4/9
control arm;
18/23
superﬁcial
and deep
intervention
arm and 3/9
control arm
4 limbs open femoral
thrombectomy and
vein patch
angioplasty for
“critically
compromised” inﬂow
“Oral
anticoagulation” 3e6
months if reversible
DVT cause (4
patients); 75 mg
clopidogrel 4 weeks
then 81 mg of aspirin
for life (all patients)
CVD severity
(C of CEAP);
symptom
relief; ulcer
healing;
complications
Neglen
200735
Retrospective
before and
after study
Failure of conservative
management (conﬁrmed with
authors) þ suspected of having
iliac vein obstruction (any of
occlusion/stenosis on
ascending/transfemoral
venogram, raised arm-foot
venous pressure differential,
abnormal hyperaemia-induced
venous pressure, presence of
pelvic collaterals vessels on
venogram)
Median
45
(range
14e90)
2.6 Thrombolysis before
procedure; < 50%
stenosis on IVUS,
minimal/no balloon
wasting on
angioplasty and no
venous recoil
870 (982): 464
limbs PTS, 518
NIVL
963
Wallstent, 19
nitinol
(brand not
stated)
920/62 396/982
superﬁcial
alone; 164/
982 deep
alone; 76/
982
superﬁcial
and deep
197 superﬁcial vein
interventions (52
limbs GSV laser
ablation; 68 limbs
GSV stripped; 55
limbs GSV
radiofrequency
closure; 7 limbs SSV
stripped, 15 limbs
stab avulsion)
5000 IU dalteparin
BD 36e48 h post
procedure (all
patients); warfarin if
thrombophilia screen
positive/recurrent
VTE/already taking;
aspirin 81 mg OD or
2 tablets/week if on
warfarin (lifelong, all
patients)
Disease
speciﬁc QOL
(CIVIQ);
symptom
relief; ulcer
healing; stent
patency;
complications
Hartung
200931
Before and
after study
Chronic symptomatic disabling
obstructive iliocaval
lesions þ failed conservative
management
Median
43
(range
16e79)
4.2 Life expectancy < 5
years; pregnancy;
malignant
obstruction
87/89
successful: 30
patients PTS, 52
NIVL, 5
retroperitoneal
ﬁbrosis, 2
congenital
obstruction
All Wallstent 59/30
patients
Not stated 3 left ovarian vein
embolisations; 1 IVC
clip resection; 2 left
GSV resections; 1 left
SSV resection; 1 left
medial
grastrocnemian vein
resection; 1 skin graft
(active venous ulcer)
Pre-2003 protocol:
Fluindione on
discharge for 6
months
Post-2003 protocol:
15 days LMWH then
antiplatelet therapy
1 year (37 patients);
complex lesions (PTS
or recanalisation)
oral anticoagulation
12 months (52
patients)
Disease
speciﬁc QOL
(VDS);
symptom
relief; ulcer
healing; stent
patency;
complications
Kolbel
200932
Retrospective
before and
after study
C of CEAP  3 þ symptoms
attributed to venous
hypertension þ conservative
management failed
Median
39
(range
18e69)
1.8 Deep femoral or
femoral vein
involvement in
obstruction on pre-
op MRV/CTV;
contrast
59/62
successful (66/
69 successful):
44 patients PTS,
5 NIVL, 10
other (4 post-
All Wallstent 0/66 Not stated Not stated 6 months warfarin
(INR 2e3) all patients
Symptom
relief; stent
patency;
complications
contraindicated;
active malignancy
traumatic, 4
post-childhood
central venous
catheter, 2
post-radiation
therapy)
Raju
200936
Retrospective
before and
after study
C of CEAP 3 and/or pain/
recurrent cellulitis) þ failed
conservative management
(conﬁrmed with
authors) þ evidence of
obstructive lesion (ascending/
descending/antegrade
transfemoral phlebography,
ambulatory venous pressure
measurement, hand/foot
venous pressure differential at
rest and after tourniquet-
hyperaemia, air
plethysmography and erect
DUS with compression)
PTS diagnosed if CVD with
known previous DVT or
phlebographic ﬁndings of
previous DVT (occlusion,
stenosis, collaterals)/DUS
ﬁndings (direct visualisation of
thrombus, partial/total
incompressibility of vein)
Median
53
(range
18e92)
2.1 Thrombolysis before
procedure
131/159
successful (139/
167 successful):
167 PTS
Wallstent “in
most
patients”
0/167 111/139
patients
reﬂux and
obstruction;
26/139
obstruction
alone (data
for 2
patients
missing)
Not stated Dalteparin 2,500 IU
before and 3e5 days
post-procedure (all
patients); warfarin if
thrombophilia screen
positive/already
taking; fondaparinux
4e6 weeks
(prophylactic dose
unless  3 venous
segments stented,
suprarenal stent,
thrombophilia or on
warfarin already in
which case
therapeutic dose
given) (all patients);
long-term aspirin
used earlier in study
before fondaparinux
introduced
Disease-
speciﬁc QOL
(CIVIQ);
symptom
relief; ulcer
healing; stent
patency;
complications
Rosales
201040
Retrospective
before and
after study
Severe chronic venous signs/
symptoms þ impacting on
function þ haemodynamically
signiﬁcant (on
plethysmography/venous
pressure gradient) venous
outﬂow obstruction on imaging
(transfemoral/popliteal
venogram or CT)
Median
41
(range
15e63)
1.3 PT occlusion to the
level of popliteal vein
32/34
successful (32/
34 successful):
34 PTS
All Wallstent 0/34 18/34 deep
reﬂux and
obstruction
2 AVF creation; 1
vein plasty
(procedures
considered if slow
ﬂow or caudal post-
thrombotic changes)
Dalteparin 100 IU/kg
BD pre-, peri-, and
postoperatively;
warfarin (all patients)
e lifelong if
thrombophilia screen
positive, otherwise
case-by-case
discussion with a
haematologist
Symptom
resolution;
ulcer healing;
stent
patency;
complications
Meng
201134
Retrospective
before and
after study
Failure conservative
management þ CVD signs (C of
CEAP  C3) þ venographic
criteria (deﬁned) or
intraoperative pressure
gradient criteria (deﬁned)
Median
43
(range
15e63)
1.2 Nil stated 272/283
successful (272/
283 limbs
successful): 283
NIVL
Not stated Combination
(not
speciﬁed)
Not stated 170 patients
saphenous stripped
and ligated within 2
months of stenting
Not stated Symptom
resolution;
ulcer healing;
stent
patency;
complications
Ye 201225 Retrospective
before and
after study
CVD (severe pain/oedema
impacting on function or CVD
signs/symptoms in left lower
limb unrelieved by
EVLA) þ NIVL (CTV or
Median
50.5
(range
31e79)
1.6 Vascular
malformation; acute/
chronic DVT; PTS;
pelvic malignancy;
retroperitoneal
205 (224): 224
NIVL
All Wallstent Not stated 54/224 deep
alone; 60/
224
superﬁcial
alone; 72/
117 patients (132
limbs) EVLA for
superﬁcial
insufﬁciency
4000 IU LMWH BD
for 2e3 days (all
patients); 75 mg OD
clopidogrel for 6
months (all patients)
Disease
speciﬁc QOL
(partial use of
CIVIQ);
symptom
Continued
Table 1-continued
Study Study design Inclusion criteria Age Female/
male
ratio
Exclusion criteria Sample size
patients (No.
limbs):
aetiology PTS,
NIVL
Stent type
(in no. limbs
unless
otherwise
stated)
Stenosis/CTO
(no. limbs
unless
otherwise
stated)
Concurrent
reﬂux at
baseline/
limb (unless
otherwise
stated)
Concurrent
endovascular/
surgical deep or
superﬁcial venous
interventions
Antithrombotic
regimen
Relevant
outcomes
reported at
6 months
transfemoral venography
[stenosis >50% on CTV, or
>50% on venography with
collaterals])
ﬁbrosis; pelvic
radiation; active
bleeding; renal
failure; not
consenting to stent
placement (total of
92 patients during
study period
excluded from
analysis)
224 deep
and
superﬁcial;
38/224
obstruction
alone
resolution;
ulcer healing;
stent
patency;
complications
De Wolf
201329
Retrospective
before and
after study
CVD (chronic CEAP C4e6 or
venous claudication) þ signs of
deep venous occlusion on DUS
or MRV
Mean
44
(range
18e75)
2.5 DVT within 1 year;
CDT before stenting
63 (75): 54
patients PTS, 9
NIVL
Sinus-XL,
Wallstent,
Zilver Vena,
Andrastent
XL
(proportions
not stated)
24/39
patients
Not stated 8 limbs
endophlebectomy
 4 AVF additionally
due to insufﬁcient
inﬂow
Aceoncoumarol or
phenprocoumon (INR
2.5e3.5)  6 months
(all patients)
Symptom
resolution;
stent
patency;
complications
Raju
201437
Retrospective
case series
As per Raju 200936 Median
58
(range
17e96)
2 As per Raj 2009 184 (217): 75%
PTS, 25% NIVL
All limbs
Wallstent
and
Gianturco Z
stent
208/9 Not stated Not stated Long-term
anticoagulation (if
thrombophilia,
recurrent
thrombosis,
unprovoked
thrombosis);
LMWH  weeks then
long term aspirin (all
patients not
anticoagulated)
Stent
patency;
complications
Sang
201438
Retrospective
before and
after study
Venous symptoms due to
venous hypertension with C of
CEAP  3 and failure of
conservative
management þ deep femoral/
femoral vein free of
obstruction on
venography þ occlusions > 6
months
Mean
44.0
(range
24e72)
0.9 Contraindication to
contrast media;
evidence of active
malignancy
63/67
successful (63/
67 successful):
67 PTS
Wallstent for
femoral
inﬂow,
S.M.A.R.T. or
Luminexx for
outﬂow
Combination
(not
speciﬁed)
22/67 reﬂux
and
obstruction;
45/67
obstruction
alone
18 temporary AVF 6
weeks (residual
femoropopliteal vein
stenosis >50%); 5
patients GSV and 4
patients
communicating vein
branch ligated and
stripped after
stenting for severe
swelling/non-healing
ulcer respectively
Warfarin (INR 2e2.5)
6 months (all
patients)
Symptom
resolution;
ulcer healing;
stent
patency;
complications
Blanch
Alerany
201426
Retrospective
before and
after study
PTS lesion (history of DVT/
suspected DVT or PT signs on
DUS/phlebogram: occlusion,
reduction more then 50%
diameter in 2 oblique planes
Median
50
(range
19e83)
1.2 Extensive obstructive
lesions (involving
femoral, popliteal,
distal veins and poor
inﬂow)
36 (39/41 limbs
successful): 41
PTS
36 Wallstent
3 Zilver Vena
15/26 20/41 deep
alone; 2/41
superﬁcial
and deep
Not stated 2 dose prophylactic
LMWH in 24-hour
post-procedure
period;
long-term
CVD severity
(Villalta,
VCSS); ulcer
healing; stent
with collaterals) þ C of
CEAP  3 or  2 and pain
requiring narcotics þ failed to
improve CEAP/VCSS with 6
months of conservative
management
anticoagulation (if
thrombophilia (17
patients), 3 venous
segments stented (8
patients), already on
anticoagulation (4
patients)); 100 mg
aspirin OD otherwise
(5 remaining
patients)
patency;
complications
Catarinella
20128 and
201527
Prospective
before and
after study
Chronic C of CEAP C4e6 or
venous
claudication þ imaging-
conﬁrmed obstruction (DUS
and MRV)
2014
study:
Mean
44
(range
18e73)
2015
study:
Mean
43.5
(range
17e77)
2014
study:
4.1
2015
study:
2.3
Nil stated 2014 study: 54:
32 patients PTS,
9 patients
“extended PTS”,
13 NIVL
2015 study:
153: 67
patients PTS, 45
“extended PTS”,
41 NIVL
Not stated Not stated Not stated 2014 study: 9
extended PTS
patients
endophlebectomy
and AVF for
insufﬁcient inﬂow
2015: 45
endophlebectomy
and AVF
Not stated Disease
speciﬁc QOL
(VEINES-QOL,
VEINES-Sym);
generic QOL
(SF-36); stent
patency
Liu 201433 Prospective
before and
after study
Symptoms of left limb
CVD þ iliac vein compression
(DUS, ascending venogram,
CTV evidence > 50% reduction
in lumen with collaterals and
pressure gradient > 2 mmHg)
PTS:
mean
41.8 (25
e73)
NIVL:
mean
39.4 (21
e78)
PTS: 3
NIVL: 2
Age < 18; pregnant;
history of pelvic
surgery/
radiotherapy/left
iliac vein injury;
contraindication to
anticoagulation or
iodinated contrast
media; CVD
secondary to pelvic
tumour/Klippel
eTrénaunay
syndrome;
malignancy with <1
year estimated
survival
46/48
successful (46/
48 successful):
12 patients PTS,
36 NIVL
All Wallstent Not stated 15/48
superﬁcial
alone; 14/48
deep alone;
12/48
superﬁcial
and deep
Not stated Warfarin (INR 2e3) 6
months (all patients)
(1 year in PTS then
review based on
symptoms);
antiplatelet therapy
continued if already
receiving
Symptom
resolution;
ulcer healing;
stent
patency;
complications
Sarici
201424
Prospective
before and
after study
Chronic PTS (signs/symptoms
of CVI in a limb previously
affected by
DVT) þ venographic evidence
of obstruction (occlusion,
pelvic collaterals)
Median
58
(range
23e76)
3 Acute cases 52/52 (59/59):
59 PTS
All nitinol
stents (brand
not stated)
Combination
(not
speciﬁed)
47/59 reﬂux
and
obstruction;
12/59
obstruction
alone
5 patients GSV strip Lifelong warfarin
(INR 2e3) if
thrombophilia (21/52
patients screened
positive); 2 months
clopidogrel followed
by lifelong aspirin (all
patients)
Disease-
speciﬁc QOL
(CIVIQ-20);
CVD severity
(Villalta
score, VCSS);
symptom
resolution;
ulcer healing;
stent
patency;
complications
Continued
Figure 2. Risk of bias summary. Green symbols represent low risk,
red represent high risk, and for yellow the risk is unclear.
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.improvements (p < .001) in all ﬁve domains of the CIVIQ-2
and the mean score fell from 63.9/100 to 50.9 (data from
128/139 CTO PTS limbs they successfully recanalised).
However, the duration of follow-up for this questionnaire is
unclear. Catarinella et al.27 demonstrated sustained signiﬁ-
cant improvements in VEINES-QOL and VEINES-Sym scores
from 46.9/100 (19.9) and 45.3/100 (22.0) to 69.6 (23.9) and
63.5 (30.5) respectively for their 153 mixed PTS and NIVL
patients at 24 months (p ¼ .013 and p ¼ .016 respectively).
Those who experienced “successful procedures” (not clearly
deﬁned, but implies it is linked to patency) demonstrated
higher QOL scores than the 33 patients who “failed” who
demonstrated no improvement (VEINES-QOL and VEINES-
Sym 47.0 [20.4] and 45.1 [22.4] to 75.4 [22.5] and 68.4
[28.1] with successful treatment vs. 47.6 [13.0] and 50.2
[17.1] to 44.4 [9.3] and 44.0 [37.0]). In their initial publi-
cation,28 they demonstrated that for 33 of 54 of their mixed
PTS and NIVL patients at 1 year there were signiﬁcant im-
provements (p ¼ .015) in one of the eight domains in the
SF-36 (physical functioning) and no domains worsened.
Table 2. GRADE assessment of the evidence.
Outcomes Relative effect
(95% CI)
No of events (studies) Quality of
the evidence
(GRADE)
Severity of chronic venous disease
Validated measures of CVD
severity (CEAP, Villalta if post-
thrombotic, etc.)
Follow-up: 6e38 months
Not estimable 295 patients stented
(5 studies24,26,30,31,39)
4222
very lowa,b
Other signs/symptoms of CVD
See Table 3
Follow-up: 6e48 months
Not estimable 1984 patients stented
(14 studies24e26,29e36,38e40)
4222
very lowc
Ulcer healing
Complete healing (re-
epithelialization)
Follow-up: 0e46 months
Not estimable 400 ulcers (12
studies24e26,30,31,33e36,38e40)
4422
lowd,e
Quality of life
SF-36, CIVIQ-2, CIVIQ-20,
VEINES-QOL and VEINES-Sym
Follow-up: 6e48 months
Not estimable 340 patients or limbs stented
(3 studies24,27,36)
4222
very lowf
Stent patency
% patent
Follow-up: 6e48 months
Not estimable 2410 limbs stented
(15 studies24e27,29,31e40)
4222
very lowg
Complications
Incidence (%)
Follow-up: 6e48 months
Not estimable 599 complications
(15 studies24e26,29e40)
4222
very lowh,i
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conﬁdence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our conﬁdence in the estimate of effect and may change the
estimate.
Low quality: Further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to change
the estimate.
Very low quality: We are very uncertain about the estimate.
CVD ¼ chronic venous disease; CIVIQ ¼ Chronic Venous Insufﬁciency Questionnaire; SF-36; Short Form Health Survey; VEINES-QOL/
Sym ¼ Venous Insufﬁciency Epidemiological and Economic Study instrument-Quality of Life/Symptoms.
a Delis et al.30 excluded participants from analysis if stents occluded (unclear how many). Large unexplained loss to follow-up at 12 months
in Blanch Alerany et al.26: 29/39 limbs available. No mention of blinding of outcome assessors/participants.
b Considered upgrading due to patients with stent occlusions experiencing less improvement (Blanch Alerany et al.26 and Sarici et al.24),
but GRADE handbook states evidence should not be upgraded, if any downgrades made.
c Studies at serious risk of selection, detection, performance, attrition and selective reporting biases (see quality assessment of studies
section).
d Loss to follow-up of studies (Ye et al. 201225, Ye et al. 201439, and Meng et al.34) and possibility of selection bias in Delis et al.30
e Persistent demonstration of healing (objective) where conservative measures had failed.
f Large risk of selection bias in Catarinella et al. 201527 and follow-up duration unclear in Raju et al. 2009.36
g Studies at serious risk of selection, detection and attrition biases (see quality assessment of studies section).
h Large loss to follow-up in Rosales et al.40 and De Wolf et al.29 (also unclear follow-up rate in several others) placing outcome at risk of
selection bias and complications reported were not predeﬁned (exception of Liu et al.33) so risk of selective reporting bias.
i Minor complication rates varied likely due to the nature of complications that where reported, e.g. back pain.
Endovenous stenting in chronic venous disease 109Sarici et al.24 found that the median CIVIQ-20 score signif-
icantly improved (p < .001) from 64 of 100 to 83 in their 59
PTS patients at 6 months after intervention (100% follow-up
rate).Stent patency
Fourteen studies reported data on stent patency (a total of
2,410 limbs stented),24e27,29,31e40 with follow-up duration
ranging between 6 months24 and a median of 4 years.25 The
last available, overall primary patency rates ranged from
32%36e98.7%.25 The same studies also reported the lowest(58%36) and the highest (100%25) AP patency rates. The
lowest secondary patency rate was also in Raju and Neglen’s
2009 study36 at 66% and the highest was 96% in two
studies.29,37 The patency data are summarised in Table 4.Complications
Fifteen studies provided data regarding complications,
reporting a total of 599 (25 major).24e26,29e40 One study
reported one unrelated death;31 six studies speciﬁcally
stated that there was no 30-day or perioperative mortal-
ity,24,25,31,35,36,38,39 and six studies stated no mortality
Table 3. Signs and symptoms of CVD and ulcer healing outcomes.
Study Baseline C of
CEAP (frequency
unless
otherwise
stated)
Signs and symptoms of CVD Ulcer healing Follow-up duration (rate)
Delis 200730 Intervention: 13
limbs C3, 4 C4, 6
C6
Control: 1 C0, 3
C1, 3 C2, 2 C4
Intervention arm: 15/23 limbs
claudication “eliminated”
(p < .001)
Intervention: 5/6 (83.3%)
ulcers healed (according
to change in CEAP class)
Median 8.4 months (100%)
Neglen
200735
7% C2, 46% C3,
24% C4, 5% C5,
17% C6
Pain: VAS 3.7 (0e9) to 0.8 (0
e10) (p < .001)
Severe pain prevalence
(VAS  5): 41%e11%
Swelling score: 1.7 (0e3,
0 ¼ absent, 3 ¼ massive,
encompassing entire leg) to 0.8
(0e3) (p < .001)
Severe swelling prevalence
(grade 3): 36%e18%
101/148 (68.2%) healed
e 8 recurred
Cumulative 5 year ulcer
healing rate: 58%
Signs/symptoms: mean 2 years
(918/982 limbs);
Ulcers: mean 23 months, (148/
158 ulcers)
Hartung
200931
15 limbs C2s, 59
C3s, 7 C4s, 2 C5s,
6 C6s
43/45 (96.5%) patients venous
claudication “improved”
23/26 (88.5%) patients pelvic
congestion “improved”
6/6 (100%) healed Median 38 months (100%)
Kolbel
200932
2 patients C3,
17 C4, 12 C5
and 8 C6
Patient reported (via telephone):
15/66 (22.7%) limbs
asymptomatic (all had symptoms
pre-procedure), 29/66 (43.9%)
moderate improvement, 5/66
(7.6%) mild improvement, 13/66
(19.7%) unchanged, 4/66 (6.1%)
worse
Median 32 months (IQR 9e74)
(100%)
Raju 200936 3 limbs C2, 71
C3, 14 C4a, 8
C4b, 11 C5, 32
C6
Cumulative improvement in pain
relief (relieved/partially
improved (3 points on VAS)):
79%
Complete pain relief: 69%;
Cumulative improvement in
swelling (relieved/partially
improved (1 grade as per
Neglen 07 scale)): 66%
Complete swelling relief: 35%
Cumulative ulcer healing
rate: 56% (32 ulcers at
baseline)
Pain: cumulative follow-up 48
months, mean/median unclear
(94/139 patients at ﬁrst follow-
up, otherwise follow-up rate
unclear)
Swelling: cumulative follow-up
48 months, mean/median
unclear (112/139 patients at
ﬁrst follow-up, otherwise
follow-up rate unclear)
Ulcer: cumulative follow-up 33
months, mean/median unclear
(58/65 at ﬁrst follow-up,
otherwise follow-up rate
unclear)
Rosales
201040
27 patients C3,
7 C6
Claudication and oedema and
pain resolved in all 32 patients
successfully recanalised
4/7 (57.1%) healed at 4
months, other 3/7 needed
valve transplantation to
achieve healing
Median 33 months (1e96)
(rate unclear)
Meng 201134 Not stated Varicose veins: 158/160 (97.8%)
“disappeared”
Leg oedema: 74/88 (84%)
“disappeared”, 10/88 (11.4%)
“improved”, 4/88 (4.5%) “no
change”
Skin pigmentation: 121/139
(87.1%) “improved”
60/70 (85%) healed, 23 by
the time of discharge
after stent (maximum 8
days)
Median 46 months (3e120)
(231/283 limbs)
110 M.J. Seager et al.
Table 3-continued
Study Baseline C of
CEAP (frequency
unless
otherwise
stated)
Signs and symptoms of CVD Ulcer healing Follow-up duration (rate)
Ye 201225 11 limbs C0, 3
C1, 7 C2, 82 C3,
26 C4, 33 C5, 62
C6
Pain: VAS 4.3 (0e9) to 0.4 (0e9)
(p < .001)
Pain (any): 115/224 (51.3%)
limbs to 13/224 (7.3%)
Cumulative oedema relief:
156/175 (89.1%) limbs
51/62 (82.3%) healed Median 4 years (180/224
limbs)
De Wolf
201329
8 patients C1s,
13 C2s, 14 C3s,
14 C4s, 8 C5s, 6
C6s
Total relief of symptoms 35/63
(55.6%) patients, partial
improvement in 12/63 (19.0%),
no improvement in 11 (17.5%)
Mean 8.8  8.0 (1e31)
months (36/63 patients and
19/63 available at 6 and 12
months respectively)
Raju 201437 4 limbs C2, 74
C3, 61 C4a, 35
C4b, 15 C5, 28
C6
Sang 201438 3 patients C2,
11 C3, 30 C4, 20
C5, 3 C6
49/58 (84.5%) patients lower
extremity symptoms “alleviated”
39/42 (92.3%) venous
claudication patients “some
improvement”
3/3 (100%) healed Mean 36.2 months (1e84)
(58/67 patients)
Blanch
Alerany
201426
2 patients C2,
20 C3, 8 C4, 2
C5, 4 C6
Oedema prevalence: 56% limbs
to 11%
5/5 (100%) healed Mean 21 months (3e48) (29/
39 limbs and 12/39 available at
12 and 24 months respectively)
Catarinella
201428 and
201527
Not stated
Liu 201433 19 limbs C2, 10
C3, 6 C4, 5 C5, 5
C6
Pain: PTS VAS median 4.5 (1e9)
to 1.2 (0e4) (p < .05) and NIVL
3.3 (0e8) to 0.3 (0e3) (p < .05)
Oedema score: PTS median 2.0
(0e3, 0 ¼ absent, 3 ¼ entire leg)
to 1.0 (0e3) (p < .05) & NIVL 1.5
(0e3) to 0.6 (0e3) (p < .05)
No change varicose veins
prevalence (45 limbs at baseline)
PTS 3/4 (75%) healed and
NIVL 2/3 (66.7%) healed;
Median time to healing 5
months
1 year (44/48 followed up)
Sarici 201424 19 patients C3,
12 C4a, 12 C4b,
1 C5, 8 C6
Oedema (mean calf
circumference in cm 2 cm below
tibial tuberosities): right 445 to
433.1 (p < .001) and left 433.9
to 411.9 (p < .001)
Oedema (mid-thigh): right 611.1
to 588.4 (p < .001) & left 599.2
to 566.3 (p < .001)
Venous claudication: 36/59
(69%) patients “ameliorated”
6/8 (75%) healed (2 limbs
with non-healing ulcers
had stents re-occlusion)
6 months (100%)
Ye 201439 2 limbs C2, 38
C3, 30 C4, 2 C5,
46 C6
Severe oedema prevalence (in
91/118 limbs) fell 70%
Severe pain prevalence
(VAS > 5/10) (in 68/118 limbs)
fell 72%
Cumulative ulcer healing
rate: 78% (46 ulcers at
baseline)
Median 26 months (1e52)
(87/110 for Villalta)
PTS ¼ post-thrombotic syndrome; NIVL ¼ non-thrombotic iliac vein lesions; VAS ¼ visual analogue score.
Endovenous stenting in chronic venous disease 111during the entire follow-up.26,29,33,34,37,40 There was one
stent fracture29 and no reports of pulmonary emboli.
The percentage of major complications per limb stented
ranged from 0%24,34,38,40 to 8.7%.30 Of note, three studiesreported contralateral DVTs (1.1% per limb stented,35
2.2%,36 and 2.2%33). Stent migration occurred in four
studies25,31,33,37 (range 0.9%37 to 4.3%33), with further
stenting required to ﬁx the stent or surgical removal. The
Table 4. Stent patency, complications and stent site data from the included studies.
Study Patency (%) Complications (% per limb
stented, unless otherwise stated)
Patency follow up
duration (rate)
Stent site as
describedPrimary AP Secondary
Delis 200730 1 iatrogenic neck haematoma
(managed with open surgery day
2) (4.3)
1 heparin-induced
thrombocytopaenia (4.3)
1 right femoral pseudoaneurysm
(managed with open surgery)
(4.3)
1 iliac stent thrombosis (further
stenting performed in “hours” of
index procedure) (4.3)
2 major (haematoma,
pseudoaneurysm)/23 stented
limbs (8.7)
3 limbs CFV to EIV;
4 CFV to CIV; 9 CFV
to IVC; 7 CIV to IVC;
10e15 mm overlap
into IVC ostium (if
CIV stented)
Neglen 200735 67 overall; 79 NIVL; 57
PTS (p < .001 vs. NIVL)
89 overall; 100 NIVL; 80
PTS (p < .001 vs. NIVL)
93 overall; 100 NIVL; 86
PTS (p < .001 vs. NIVL)
No 30 day mortality
14 early (<30 day) ipsilateral
DVT/stent thrombosis (1.4)
23 late (30 day) ipsilateral
DVT/stent thrombosis (2.3)
11 contralateral DVT (4 early, 7
late) (1.1)
6 access related complications (2
in ﬁrst 29 cases, then 4 in next
953 after ultrasound guidance
introduced) (0.6)
1 wire caught in stent (open
removal) (0.1)
2 major (1 access related
complication e needed open
surgery, 1 wire caught in stent)
982 stented limbs (0.2)
Mean 30 months
(610/982 limbs)
Methods state if
lesion near iliac
conﬂuence, stent
placed “well into
IVC”, but exact sites
stented not stated
Hartung 200931 83 overall; 86.3 NIVL;
83.2 PTS
Patency per
aetiology ¼ unpublished
data, statistical
signiﬁcance unclear
89 overall; 95.1 NIVL; 81.3
PTS
Patency per
aetiology ¼ unpublished
data, statistical
signiﬁcance unclear
93 overall; 95.7 NIVL; 88
PTS
Patency per
aetiology ¼ unpublished
data, statistical
signiﬁcance unclear
2 recanalisation failures
No peri-operative death/PE
No contralateral occlusions
despite 9 left CIV stenting
protruding to IVC
5 procedural complications: 2
stent migrations (both snared, 1
removed surgically, 1 further
stent deployed), 1 SFA tear, 2
contrast extravasation (5.7)
5 post-procedure complications:
43 patients
treated > 4 years
before analysis
median 68 months
(49e144) (100%);
46 patients
treated < 4 years
before analysis
median 20 months
(1e43) (100%)
8/87 limbs beneath
inguinal ligament
112
M
.J.
Seager
et
al.
2 thromboses (1 open
thrombectomy), 1 right
haemothorax (drained), 2 access
site haematomas (conservative
management) (5.7)
10 late post-procedure
complications: 1 unrelated, 3
thromboses, 6 restenoses (11.5)
3 major (2 stent migrations, 1
haemothorax)/87 stented limbs
(3.4)
1 death at 16 months (peritoneal
carcinosis due to colon cancer)
Kolbel 200932 67 75 79 3 recanalisation failures
No symptomatic PE
2 patients retroperitoneal bleed
(procedure abandoned and both
patients transfused) (3.0)
1 minor access site bleed (1.5)
12 limbs reintervention: 6
further venoplasty, 3 restented
(stent stenosis), 3 restented
(recurrent iliac thrombosis)
(18.2)
14 limbs (11 symptomatic)
residual occlusion at last follow-
up (21.2)
2 major (2 bleeds and
transfusions)/66 stented limbs
(3.0)
Median 25 months
(9e48 IQR) (100%)
46/66 limbs
beneath inguinal
ligament
Raju 200936 32 58 66 28/167 recanalisation failures
No 30 day mortality
No access site/bleeding
complications
“About 25% of patients” back
pain <2 weeks relieved with
simple analgesia;
1 transient contrast-related renal
impairment (0.7)
10 early (<30 day) ipsilateral
DVT/stent thrombosis (7.3)
32 late (30 day) ipsilateral
DVT/stent thrombosis (23.5)
3 contralateral DVT (all late)
Cumulative follow-
up 4 years, mean/
median unclear
(122/139 limbs at
ﬁrst follow-up,
otherwise follow-
up rate unclear)
Caudal landing
zone in CFV in 65/
139 limbs; in EIV
42/139 and CIV in
32/139
Cephalad landing
zone in IVC in all
but 2 limbs
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Table 4-continued
Study Patency (%) Complications (% per limb
stented, unless otherwise stated)
Patency follow up
duration (rate)
Stent site as
describedPrimary AP Secondary
(2.2)
1 major (renal impairment)/136
stented limbs (0.7)
Rosales 201040 66.7 76.2 90.5 2/34 recanalisation failures
No mortality
13/34 symptom recurrence: 2
stent stenoses, 11 stent
occlusions (40.6)
0 major/32 stented limbs
33 months (1e96)
(21/32 patients)
22/32 limbs stent
stack iliofemoral; 9/
32 purely iliac and
1/32
femoroiliocaval
Meng 201134 91.7 11/296 patients recanalisation
failures
No mortality or PE
13 stent thromboses (4.8)
6 stent stenoses (2.2)
0 major/272 stented limbs
Cumulative follow-
up 5 years, mean/
median unclear
(100% had 1 DUS,
151/296 had 2,
otherwise follow-
up rate unclear)
Methods state iliac
vein, but exact sites
stented not stated
Ye 201225 98.7 100 No perioperative/early (<30
days) death, DVT, PE
Back pain 34/205 (self-limiting)
(15.2);
3 stent migration (additional
stents deployed) (1.3);
2 bleeding at site (conservatively
managed) (0.9)
3 major (3 stent migrations)/
224 limbs stented (1.3)
Duration and rate
unclear
Methods state
stent extended
1 cm cephalad into
IVC where CIV
ostium involved
and the caudal
landing
zone > 2 cm
beyond lesion, but
exact sites stented
not stated
De Wolf 201329 74 81 96 No clinically evident PE or stent
migration and no periprocedural
death/unrelated death
11 early (<30 day) stent
reocclusion/thrombosis (14.7)
7 late (>30 day) stent
rethromboses (9.3)
15 stent stenoses (3 clinically
haemodynamically signiﬁcant)
(20)
6 bleeding complications (1 open
surgery) (8.0)
1 heparin induced
thrombocytopaenia (1.3)
2 superﬁcial wound problems
Cumulative follow-
up 12 months,
mean/median
unclear (rate
unclear)
Methods state iliac
vein, but exact sites
stented not stated
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after surgical endophlebectomy
(2.7)
2 stent kink, 1 stent fracture, 2
stent pain (6.7)
6 major (1 open surgery, 5 stent
kinks/fracture/pain all
restented)/75 stented limbs
(8.0)
Raju 201437 69 96 No mortality
2 Z stent migration (both ﬁxed
with further stent) (0.9)
“About 25% patients” modest
self-limiting back pain
Early (<30 days) DVT (4% per
person stented)
Late (.30 days) DVT (1% per
person)
8 entire stent stack thrombosis
(2.6)
2 major (2 stent migrations)/
217 stented limbs (0.9)
Cumulative follow-
up 24 months,
mean/median
unclear (rate
unclear)
Methods state iliac
vein and also IVC to
some degree
stented, but exact
sites stented not
stated
Sang 201438 70.7 82.8 4/67 limbs recanalisation failure
No 30-day mortality, major
bleeding, cardiac, renal,
pulmonary complications
5 iliac vessel perforation
(conservatively managed) (7.9)
3 early (30 days) stent
thrombosis (4.8)
11 late (>30 days) stent
occlusions (17.4)
6 (>30 days) stent restenosis
(9.5)
0 major/63 stented limbs
Mean 36.2 months
(1e84) (58/67
limbs)
29/63 limbs CIV to
CFV; 20/63 CIV to
EIV; 14/63 CFV to
EIV
Inﬂow at least 1 cm
caudal to lesion
and outﬂow no
more than 0.5 cm
into IVC if
applicable
Blanch Alerany
201426
74 (95% CI 67e81) 87 (82e92) 89 (83e94) 241 limbs recanalisation failures
No mortality
1 femoral artery
pseudoaneurysm (treated with
ultrasound guided compression)
(2.6)
3 limbs early (<4/52) stent
occlusion (7.7)
4 limbs late stent occlusion
(10.2)
Cumulative follow-
up 33 months,
mean/median
unclear (31/34
patients)
Caudal venous
segment beneath
inguinal ligament in
22/39 and all 39
limbs 4 cm into IVC
Continued
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Table 4-continued
Study Patency (%) Complications (% per limb
stented, unless otherwise stated)
Patency follow up
duration (rate)
Stent site as
describedPrimary AP Secondary
2 limbs stent stenoses (5.1)
1 major complication
(pseudoaneurysm)/39 stented
limbs (2.6)
Catarinella 201527 65 (SEM < 10%) 78 (SEM < 10%) 89 (SEM < 10%) 2 years Not stated
Liu 201433 93 overall; 96.9 NIVL;
81.8 PTS (p ¼ .156)
2/48 patients recanalisation
failures
No deaths, PE, contrast induced
nephropathy
2 stent migration during
procedure (further stents
deployed) (4.3)
1 iliac vein rupture during
procedure (required open
surgery) (2.2)
4 local haematomas
(conservatively managed) (8.7)
3 DVT at 1 year (2 stent, 1
contralateral calf) (6.5)
41 back pain 1 month and 3 at 1
year (89.1)
3 major (2 stent migrations, 1
iliac vein rupture)/46 stented
limbs (6.5)
Cumulative follow-
up 1 year, mean/
median unclear
(rate unclear)
Not stated
Sarici 201424 86 90 No early (<30 days)
postoperative mortality/
morbidity
6 stent occlusions at 6 months
(10.2);
1 stent stenosis at 6 months
(1.7)
0 major/59 stented limbs
6 months (100%) Methods state iliac
vein with cephalad
stent extension
1 cm into IVC
Ye 201439 70 90 94 No perioperative death/PE
6/118 limbs recanalisation
failures
21 stent stenoses
88 back pain (self-limiting,
resolved during stay) (78.6)
47 venous perforations no
change in management to iliac
vein stenting) (42.0)
3 years (13/104
patients no follow-
up)
Methods state
below inguinal
ligament “if
needed” and 2 cm
extension into IVC
CFV ¼ common femoral vein; CI ¼ conﬁdence interval; DUS ¼ duplex ultrasound; DVT ¼ deep vein thrombosis; EIV ¼ external iliac vein; CIV ¼ common iliac vein; IQR ¼ interquartile range;
IVC ¼ inferior vena cava; NIVL¼ non-thrombotic iliac vein lesions; PE ¼ pulmonary embolism; PTS ¼ post-thrombotic syndrome; SEM ¼ standard error of the mean; SFA¼ superﬁcial femoral
artery.
Major complications are highlighted in bold.
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Endovenous stenting in chronic venous disease 117percentage of stent occlusion/DVT and stent stenosis per
stented limb ranged from 3.8%35 to 34.4%40 and 1.7%24 to
20%29 respectively in the 1324,26,29e38,40 studies reporting
these data separately from their patency outcomes. The
reported complications are summarised in Table 4.Subgroup analyses
Where available, the data are summarised in Table 5.
Additionally, two studies used venous-speciﬁc stents in a
small number26 or unstated number of limbs29 (both Zilver
Vena; Cook Medical, Bloomington, IN, USA). Six studies
used multiple types of stents,26,29,30,35,37,38 and Blanch
Alerany et al.26 found no association between stent brand
and stent thrombosis.
DISCUSSION
Endovenous stenting is increasingly used to treat CVD
related to PTS and NIVL obstruction. This review demon-
strates that the quality of evidence supporting this is weak,
with the main ﬂaw being a lack of control groups to illus-
trate that the observed beneﬁts are not part of the natural
progression of CVD. Recent European and American
guidelines recommended endovenous stenting for severe
obstructive venous disease, but recognised that the evi-
dence is weak.10,11
It is recognised that PTS ulcers can be refractory to
conservative treatment and tend to recur6 and this review
highlighted six studies26,30,31,35,36,38 where ulcers in PTS
limbs failed to heal with conservative measures. The
consistent response of ulcer healing to stenting therefore
represents a change in the course of the disease and sug-
gests deep venous stenting is an effective therapy for re-
fractory PTS ulcers. The other ﬁve outcomes were all largely
positive, but ﬁrm conclusions about the magnitude of the
effect of endovenous stenting in CVD related to obstruction
cannot be drawn.
The importance of ensuring a true improvement in a
patient’s QOL and not just venous severity scores has
recently been demonstrated in the setting of endovenous
intervention. The CaVenT trial showed reduced rates of PTS
in patients two years after receiving catheter-directed
thrombolysis for proximal DVT compared to compression
and anticoagulation,41 but no difference in venous disease-
speciﬁc QOL scores.42 This review found general improve-
ments in the various QOL scores, but the methodological
weaknesses mean that deep venous stenting has not yet
been shown to deﬁnitely improve QOL.
If the efﬁcacy of endovenous stenting cannot be quan-
tiﬁed, it does appear to be safe, with rates of major com-
plications of less than 2% in all studies which stented over
200 limbs.25,34,35,37 Minor complications were reported at
variable rates, likely to be due to a combination of het-
erogeneous study groups and inconsistency in classifying or
reporting complications. Initiatives such as the stenting
section of the American Venous Registry43 will allow
standardisation and more precise estimates of complication
rates. The concern from arterial studies of possible stentfracture across joints does not appear to translate to venous
stenting, with one stent fracture and two stent kinks in one
study only.29
Despite initial concerns that stents in the low-ﬂow
venous system are likely to be at serious risk of throm-
bosis, all of the included studies demonstrated good
patency rates. Primary patency rate was over two-thirds at
the last follow-up in all studies apart from two,27,37 with
over 3 years’ of follow-up in several studies.25,31,34,38
Three studies found that stenting below the inguinal
ligament was associated with worse patencies35,39,40 and
three did not.26,31,32 Neglen et al.44 performed a further
analysis of their dataset that suggested that patency is not
related to extension across the inguinal ligament, but is in
fact related to aetiology with better patencies for NIVL than
PTS and for non-occlusive lesions versus CTO. This conclu-
sion is supported by the very high patency rates reported in
studies where only NIVL were stented,25,34 whereas studies
with a high proportion of CTO PTS limbs often reported less
favourable patencies.32,36 It is likely therefore that any
worse endovascular outcome with stents below the inguinal
ligament reﬂects the severity of the post-thrombotic
obstruction, rather than an inherent danger of caudal
stent extension. At the cephalic end, extending stent stacks
into the IVC appears safe, with low risk of contralateral DVT,
and two studies suggested early stent stenosis if this is not
pursued for lesions near the iliac conﬂuence.24,35
The concurrent use of superﬁcial venous interventions is
certainly a potential confounding factor; however, with the
exception of one study,25 they were performed in the mi-
nority of stented limbs24,31,35 suggesting any effect is likely
to be largely related to endovenous stenting. The data
suggest that surgical inﬂow procedures can be concurrently
performed safely, but given that stenting below the inguinal
ligament is likely to be effective, we would argue that this
should be pursued ﬁrst. There was no evidence to suggest
that stenting for obstructive lesions in patients with known
deep reﬂux worsens CVD severity, although this was
assessed in one study only.26 Raju’s group have corrobo-
rated this in a further analysis of their large dataset, which
showed that correcting the obstructive element alone of
combined obstructive and deep reﬂux disease, demon-
strates clinical improvement without deterioration in reﬂux
measures.45
The diagnosis of obstruction is beyond the scope of this
review, but the inadequacies of duplex ultrasound46 and
contrast venography47 and the need for other imaging
modalities have been documented elsewhere,11 with
intravascular ultrasound showing promise.47 Furthermore,
this review did not aim to examine the combined effect of
stenting with medical adjunctive management such as the
use of pentoxifylline11 or aspirin.48
There are therefore a number of areas for future
research. Before the practice is more widely rolled out, a
RCT should be performed comparing the practice against
conservative measures, with long-term follow-up and
outcome measures to include validated CVD measures and
QOL scores.49
Table 5. Subgroup analyses.
Subgroup analysis Study Comment
NIVL vs. PTS Neglen et al.35 Cumulative pain relief and ulcer healing rates not affected by aetiology
Primary, assisted primary and secondary patency rates were greater in NIVL limbs
than PTS (see Table 4)
All 31 stent occlusions were in patients with PTS and restenosis 50% was also
more common in PTS limbs (OR 26.7 vs. NIVL, p < .0001)
Hartung et al.31 In PTS and NIVL patients, median VDS score improved from 3 to 2 to 1 and 1
respectively, although the statistical signiﬁcance of this is unclear (unpublished data)
PTS was associated with decreased secondary (p ¼ .023), but not primary patency
(p ¼ .144) (univariate analysis)
De Wolf et al.29 Non-signiﬁcant trend for lower rates of stent thrombosis in NIVL vs. PTS (20% vs.
33%, p ¼ .124)
Catarinella et al. 201428 Greatest improvement in venous disease speciﬁc QOL at 12 months in NIVL
patients (VEINES-QOL and VEINES-sym improved from 49.7 (22.9) to 91.5 (6.8) and
from 44.9 (20.0) to 89.3 (6.7) respectively) with the “extended PTS” (stented PTS
patients also requiring endophlebectomy and AVF construction) showing no
signiﬁcant improvement in QOL scores (VEINES-QOL and VEINES-sym of 52.8 (14.6)
to 56.5 (17.5) and 54.6 (18.0) to 58.5 (28.4) respectively)
Liu et al.33 Non-signiﬁcant trend to lower primary patency at 1 year in PTS limbs (81.8% PTS,
96.9% NIVL, p ¼ .156)
CTO vs. stenosis Neglen et al.35 Stent occlusion or re-stenosis more likely in stenting of CTO limbs (OR 9.0 and 8.3
versus limbs stented for stenosis, p < .0001).
Blanch Alerany et al.26 Similar cumulative rates of VCSS improvement following stenting for both stenotic
and CTO limbs
All 9 post-procedure stenoses or thromboses (of 41 stented limbs) occurred in CTO
veins (p ¼ .04)
Stent site e above
vs. below inguinal
ligament
Neglen et al.35 Extension of stent site below the inguinal ligament associated with both stent
occlusion and stent stenosis of 50% (OR 3.8 and 5.5 respectively, p < .01)
Hartung et al.31 Stented below the inguinal ligament in the 8/87 limbs e none of which
experienced stent occlusion
In 10 limbs, the lesion extended below the inguinal ligament, but stents were not
placed into the CFV and 3 of these stent segments thrombosed (p ¼ .22)
Kolbel et al.32 No association with patency or change in symptoms when stented below inguinal
ligament
Rosales et al.40 Crossing the inguinal ligament in 21/32 PTS limbs associated with a worse primary
patency (p ¼ .0063) but similar secondary patencies
Blanch Alerany et al.26 Stenting below the inguinal ligament in 22/39 PTS limbs no effect on stent
thrombosis
Ye et al. 201439 Stenting below the inguinal ligament in PTS CTO limbs associated with higher stent
stenosis (hazard ratio 1.7e6.5 p ¼ .156)
Stent site e into
IVC
Kolbel et al.32 No change in patency or clinical outcomes and no contralateral limb DVTs or stent
migration with IVC extension
Neglen et al.35 Commenced series by avoiding stent extension into the IVC in the ﬁrst 25 cases,
but found 40% developed proximal stenoses due to caudal stent migration
After all braided stents inserted “well into” the IVC and the overall stenosis rate for
the study was 4.58% and 1.12% limbs experienced contralateral DVTs
Raju et al.36 Stented all but 2 of 131 PTS limbs into the IVC, and reported 3 contralateral DVTs
Blanch Alerany et al.26 Extended all 39 stent stacks 4 cm into the IVC and reported no contralateral limb
DVTs
Concurrent
superﬁcial venous
interventions
Neglen et al.35 Similar rates of cumulative pain and oedema freedom and ulcer healing rates with
addition of concurrent superﬁcial venous interventions
Ye et al. 201225 Similar pain and oedema scores and ulcer healing and patency rates amongst with
the addition of endovenous laser ablation for concurrent superﬁcial insufﬁciency
Presence/absence
of superﬁcial/deep
reﬂux
Blanch Alerany et al.26 Similar cumulative improvement in VCSS amongst their 36 PTS patients with and
without deep venous reﬂux
CFV ¼ common femoral vein; CTO ¼ complete total occlusion; DVT ¼ deep vein thrombosis. IVC ¼ inferior vena cava; NIVL ¼ non-
thrombotic iliac vein lesions; OR ¼ odds ratio; VDS ¼ Venous Disability Score; PTS ¼ post-thrombotic syndrome; QOL ¼ quality of life;
VCSS ¼ Venous Clinical Severity Score; VEINES-QOL/Sym ¼ Venous Insufﬁciency Epidemiological and Economic Study instrument-
Quality of Life/Symptoms.
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Endovenous stenting in chronic venous disease 119The cost-effectiveness must also be conﬁrmed. The
addition of surgical procedures to produce adequate stent
inﬂow could also be examined by registry data, as there are
unlikely to be sufﬁcient numbers of patients to assess this in
a RCT. Venous-speciﬁc stents also need clinical and technical
evaluation. The beneﬁt of standardising both the diagnosis
of PTS and NIVL and the outcome measures of CVD severity
and QOL that are used, with long-term follow-up of pa-
tients, cannot be understated.
CONCLUSION
Endovenous stenting should be considered as a treatment
option for obstructive CVD. To date, the quality of evidence
to support its use is weak, but consistent effects and
marked changes in disease course with potential impact on
QOL are promising. This review has highlighted important
areas for development of the evidence base, before the
practice is more widely rolled out.
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